Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468805 | 1.00 | KCNH2 (0.43) | KCNH2EPHX2SHBGLMNAGBA1 | |
| SCHEMBL3471037 | 1.00 | KCNH2 (0.43) | KCNH2EPHX2SHBGLMNAGBA1 | |
| SCHEMBL16584661 | 0.97 | KCNH2 (0.44) | KCNH2EPHX2SHBGLMNAGBA1 | |
| SCHEMBL8906615 | 0.91 | KCNH2 (0.38) | KCNH2EPHX2SHBGLMNAGBA1 | |
| SCHEMBL25042763 | 0.86 | KCNH2 (0.52) | KCNH2FUCA1METAP1NSD2KDM4E | |
| SCHEMBL549384 | 0.86 | — | — | |
| SCHEMBL1142602 | 0.86 | KCNH2 (0.52) | KCNH2FUCA1METAP1NSD2KDM4E | |
| SCHEMBL12750748 | 0.85 | — | — | |
| SCHEMBL12472932 | 0.85 | — | — | |
| SCHEMBL16748086 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-28 | — | — | US | disclosed |
| US-20240027902-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11774853-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-03 | — | — | US | disclosed |
| US-20230305393-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230305394-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230286902-A1 | LIPID NANOPARTICLE COMPOSITION | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230161252-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-4754077-A | HINDERED PHENOLS, METHANOL, FORMALDEHYDE, PHENOL COMPOUND, MANNICH BASE CATALYST | ETHYL CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |
| US-4692555-A | Preparation of diphenolics | ETHYL CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0116712-B1 | SYNTHESIS OF HINDERED PHENOLS | ETHYL CORPORATION (US) | 1987-03-25 | — | — | EP | disclosed |
| EP-0116712-A1 | Synthesis of hindered phenols | ETHYL CORPORATION (US) | 1984-08-29 | — | — | EP | disclosed |
| US-4113777-A | ANTISECRETORY, ANTITUSSIVE, ANTIULCER | BOEHRINGER INGELHEIM GMBH (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4101671-A | ANTIULCEROGENICS | BOEHRINGER INGELHEIM GMBH (DE) | 1978-07-18 | — | — | US | disclosed |
| US-RE29628-E | ANTIULCER, SECRETOLYTICS, ANTITUSSIVE | BOEHRINGER INGELHEIM GMBH (DT) | 1978-05-09 | — | — | US | disclosed |
| US-4073942-A | Halo-substituted hydroxybenzyl-amines as secretolytic agents | BOEHRINGER INGELHEIM GMBH (DT) | 1978-02-14 | — | — | US | disclosed |
| US-3950393-A | ANTIULCER, ANTISECRETORY, ANTITUSSIVE AGENTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KCNH2 4751/4885EPHX2 1890/4885SHBG 4694/4885 |
| US-20230286902-A1 | LIPID NANOPARTICLE COMPOSITION | CETP, NPC1, LCAT | KCNH2 4534/4885EPHX2 2487/4885SHBG 2307/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | KCNH2 874/4885EPHX2 1374/4885SHBG 1124/4885 |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, PDGFRB | KCNH2 3125/4885EPHX2 1805/4885SHBG 3263/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | KCNH2 2859/4885EPHX2 833/4885SHBG 4700/4885 |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, PDGFRB | KCNH2 3125/4885EPHX2 1805/4885SHBG 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.